SAMHSA emphasizes the importance of overdose reversal medications, suggesting a clear distinction from harm reduction strategies.
In a July 29 Dear Colleague letter, the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency with the federal Department of Health and Human Services (HHS), strongly supports the use of opioid overdose reversal medications (OORMs) – naloxone and nalmefene – and explains that these are not par of “an ideological concept of harm reduction.”
No takes yet. Share an insight, caveat, or question.
Alison Knopf (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: